Wall Street sinks on BOJ fears, Icahn comments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BTIG Positive on Abbott's (ABT) Move to Acquire St. Jude (STJ); Says Synergy Guidance Came in Above Expectations
April 28, 2016 11:54 AM EDTBTIG affirms Abbott Labs (NYSE: ABT) at Buy with a price target of $45 following news that the company was going to acquire St. Jude Medical (NYSE: STJ) in a deal value around $31 billion (including... More
S&P Affirms Negative Outlook on Abbott (ABT) Amid Move to Acquire St. Jude Medical (STJ)
April 28, 2016 11:38 AM EDTStandard & Poor's Ratings Services stated that its ratings on Abbott Laboratories (NYSE: ABT), including the 'A+' corporate credit and 'A-1+' commercial paper ratings, remain on CreditWatch with negative implications. The CreditWatch update follows Abbott's offer to acquire St. Jude Medical for roughly $31 billion (including $6 billion of assumed St. Jude debt). This transaction is in addition to the planned roughly $9 billion debt-funded acquisition of Alere.
"We believe that when completed, the acquisition of St. Jude Medical would significantly strengthen Abbott's position in the medical device industry as well as broaden its already very... More
Facebook (FB) PT Raised to $145 at Stifel
April 28, 2016 10:24 AM EDTEarlier, Stifel analyst Scott Devitt reiterated a Buy rating and boosted its price target on Facebook (NASDAQ: FB) to $145.00 (from $130.00).
Dewit commented, "Facebook beat consensus revenue / EPS by 2% / 24% in 1Q:16 as both total revenue and ad revenue did not decelerate from 4Q:15s impressive growth... More
